Welcome to our dedicated page for Septerna news (Ticker: SEPN), a resource for investors and traders seeking the latest updates and insights on Septerna stock.
Septerna, Inc. (Nasdaq: SEPN) is a clinical-stage biotechnology company focused on G protein-coupled receptor (GPCR) drug discovery and development. News about Septerna often centers on progress across its pipeline of oral small molecule GPCR-targeted therapies, updates on clinical and preclinical programs, and developments related to its proprietary Native Complex Platform™.
Investors following SEPN news can expect regular updates on key programs such as SEP-631, a selective oral small molecule MRGPRX2 negative allosteric modulator (NAM) in a Phase 1 clinical trial for chronic spontaneous urticaria and other mast cell-driven diseases, and SEP-479, a next-generation oral PTH1R agonist development candidate for hypoparathyroidism. Septerna’s news flow also includes information on its TSHR NAM program for Graves’ disease and thyroid eye disease and discovery-stage programs in endocrinology, immunology and inflammation, metabolic diseases and additional therapeutic areas.
Company announcements frequently highlight financial results, cash position and collaboration-related revenue, particularly from its global collaboration and license agreement with Novo Nordisk A/S to discover and develop oral small molecule therapies for obesity, type 2 diabetes and other cardiometabolic diseases. Septerna also issues news on corporate governance and leadership, such as board appointments, executive role changes and the formation of board committees.
In addition, Septerna regularly announces participation in major healthcare and investor conferences, where management presents business updates and pipeline overviews. For those tracking SEPN, this news page aggregates press releases and related coverage so readers can monitor clinical milestones, collaboration developments, financial disclosures and leadership changes over time.
Septerna (Nasdaq: SEPN) reported Q4 and full-year 2025 results and highlighted pipeline progress, including positive Phase 1 data for SEP-631 and IND-enabling completion for SEP-479. Cash totaled $548.7M at year-end, and management expects runway to support operations at least into 2029.
SEP-631 showed favorable safety, once-daily PK, and dose-dependent PD with near-complete inhibition at higher doses; Phase 2b in CSU planned in H2 2026.
Septerna (Nasdaq: SEPN) reported positive Phase 1 results for SEP-631, an oral MRGPRX2 negative allosteric modulator. SEP-631 showed dose-dependent inhibition of icatibant-induced skin wheals with complete inhibition at 10 mg once-daily and near-complete inhibition at 90–200 mg.
The drug was well tolerated, had an approximate 24-hour half-life, no food effect on exposure, and a PK profile supporting once-daily oral dosing. Septerna plans a Phase 2b CSU trial in H2 2026 pending long-term toxicology completion.
Septerna (Nasdaq: SEPN) announced that CEO and co-founder Jeffrey Finer, M.D., Ph.D. will present at the TD Cowen 46th Annual Health Care Conference on March 3, 2026 at 3:10 p.m. ET in Boston.
A live webcast will be available on the company investor website and will be archived for at least 30 days for on-demand viewing.
Septerna (Nasdaq: SEPN) announced an inducement stock option grant to Chief Legal Officer Mark A. Wilson on February 6, 2026. The non-qualified option covers 165,000 shares with an exercise price of $25.41, equal to the closing price on February 6, 2026, and vests over four years.
The option vests 25% after one year, with the remaining 75% vesting monthly over 36 months, subject to continued employment and plan terms.
Septerna (Nasdaq: SEPN) will present Phase 1 data for SEP-631, an oral MRGPRX2 negative allosteric modulator, at the 2026 AAAAI Annual Meeting in Philadelphia, Feb 27–Mar 2, 2026. The poster (L58) is scheduled for March 1, 2026, 9:45–10:45 a.m. ET in Hall E.
The presentation describes a first-in-human, proof-of-mechanism Phase 1 study using short wave infrared imaging to assess response to an icatibant skin challenge in chronic spontaneous urticaria and other mast cell-driven diseases.
Septerna (Nasdaq: SEPN) announced on January 8, 2026 the appointment of Mark A. Wilson as Chief Legal Officer. Mr. Wilson brings more than 25 years of pharmaceutical and biotech legal experience in intellectual property, corporate legal, strategic collaborations and governance. He joins from Nektar Therapeutics where he served as Senior Vice President and Chief Legal Officer and led global patent strategy, major development and commercialization collaborations, and alternative financings. Mr. Wilson held prior roles from Patent Counsel to General Counsel and is a J.D. from Seton Hall and a B.S. in Pharmacy from Rutgers; he is registered with the U.S. Patent and Trademark Office and a member of the California Bar.
Septerna (Nasdaq: SEPN) announced that CEO and co‑founder Jeffrey Finer, M.D., Ph.D. will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026 at 3:45 p.m. PT in San Francisco.
A live webcast of the presentation will be available in the company's investor relations section at www.septerna.com, and the webcast will be archived for at least 30 days after the presentation.
Septerna (Nasdaq: SEPN) announced management will participate in a fireside chat at the 8th Annual Evercore Healthcare Conference on December 2, 2025 at 10:25 a.m. ET in Coral Gables, Florida.
A live webcast will be available in the company's investor relations website and the webcast will be archived for at least 30 days after the presentation.
Septerna (Nasdaq: SEPN) reported third-quarter 2025 results and program milestones on Nov 10, 2025. Key program news: SEP-479 was selected as the next-generation oral PTH1R agonist for hypoparathyroidism after a 7‑day cynomolgus study showing dose‑dependent serum calcium increases and reduced endogenous PTH; a Phase 1 trial is planned in H1 2026. SEP-631 Phase 1 in healthy volunteers is ongoing with initial SAD/MAD and PD readouts expected in H1 2026. Financials: cash, equivalents, and marketable securities of $561.6M (includes $195M Novo Nordisk upfront and $12.5M Vertex milestone); Septerna expects runway into at least 2029. Q3 revenue was $21.5M, R&D expense $24.3M, G&A $7.1M, and net income $8.2M.
Septerna (Nasdaq: SEPN) announced management will participate in two investor conferences in November 2025: a Guggenheim fireside chat on November 10, 2025 at 4:00 p.m. ET and a TD Cowen Immunology & Inflammation Summit fireside chat on November 12, 2025 at 4:00 p.m. ET.
Both presentations will be live webcast and available in the investors section at www.septerna.com. Replays will be archived for at least 30 days after each event.